Lexeo Therapeutics, Inc. Interest Expense
Lexeo Therapeutics, Inc. (LXEO) reported Interest Expense of $35.00 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-12.
Discontinued
us-gaap:InterestExpense · last filed 2024-08-12
- Lexeo Therapeutics, Inc. interest expense for the quarter ending 2024-06-30 was $35.00K, a 33.96% decline year-over-year.
- Lexeo Therapeutics, Inc. interest expense for the quarter ending 2024-03-31 was $37.00K, a 26.00% decline year-over-year.
- Lexeo Therapeutics, Inc. interest expense for the quarter ending 2023-12-31 was $50.00K, a 7.41% decline year-over-year.
- Lexeo Therapeutics, Inc. interest expense for the quarter ending 2023-09-30 was $52.00K, a 79.31% increase year-over-year.
- Lexeo Therapeutics, Inc. interest expense for fiscal 2023 was $205.00K, a 125.27% increase from fiscal 2022.
- Lexeo Therapeutics, Inc. interest expense for fiscal 2022 was $91.00K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $35.00K 10-Q · filed 2024-08-12 | $72.00K 10-Q · filed 2024-08-12 | $122.00K derived: sum of 3 quarters · filed 2024-08-12 | $174.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | $37.00K 10-Q · filed 2024-05-09 | $87.00K derived: sum of 2 quarters · filed 2024-05-09 | $139.00K derived: sum of 3 quarters · filed 2024-05-09 | $192.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-12-31 | $50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $102.00K derived: sum of 2 quarters · filed 2024-03-11 | $155.00K derived: sum of 3 quarters · filed 2024-08-12 | $205.00K 10-K · filed 2024-03-11 |
| 2023-09-30 | $52.00K 10-Q · filed 2023-12-11 | $105.00K derived: sum of 2 quarters · filed 2024-08-12 | $155.00K 10-Q · filed 2023-12-11 | $209.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-06-30 | $53.00K 10-Q · filed 2024-08-12 | $103.00K 10-Q · filed 2024-08-12 | $157.00K derived: sum of 3 quarters · filed 2024-08-12 | $186.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $50.00K 10-Q · filed 2024-05-09 | $104.00K derived: sum of 2 quarters · filed 2024-05-09 | $133.00K derived: sum of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | $54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $83.00K derived: sum of 2 quarters · filed 2024-03-11 | $91.00K 10-K · filed 2024-03-11 | |
| 2022-09-30 | $29.00K 10-Q · filed 2023-12-11 | $37.00K 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |